Ideally says GLP-1 behavior shift reaches 60% of Americans

A new Ideally study says GLP-1s are influencing shopping, eating and drinking habits for 60% of U.S. adults, far beyond the number currently taking the drugs. The company says brands tracking prescriptions alone are missing a behavioral shift that is reshaping snacking and alcohol demand.

Why it matters: - Ideally says brands that track only GLP-1 prescription counts are missing a much larger consumer shift. - The company says the behavioral footprint is about six times larger than active GLP-1 use. - That shift is affecting what Americans buy, eat and drink, with direct implications for food, beverage and alcohol brands.

What happened: - Ideally released The Consumer Shift Reshaping How America Eats & Drinks, a national study of 2,184 U.S. adults. - The study says 60% of Americans now fall within the GLP-1 behavioral footprint. - Kathy Lubner, U.S. Research Lead at Ideally, said many products consumers are moving toward already exist and brands need to recognize changing priorities, occasions and packaging needs.

The details: - The footprint extends beyond people taking GLP-1 drugs. - One in seven Americans now live in a household with a GLP-1 user. - Those household members are adopting habits such as eating more protein, cooking at home and drinking less. - The study says people often describe the new habit, not the drug that triggered it. - GLP-1 use skews older, but 66% of millennials and 60% of Gen Z fall within the behavioral footprint. - Eight percent of adults have used a GLP-1 and stopped, but the behavior change persists. - The report says snacking is feeling the first impact as appetite drops and baskets become more efficient and selective. - PepsiCo, Danone and Nestlé are already responding, according to the report. - The study says alcohol is the next category to feel the shift. - The opportunity is not simply in alcohol-free products, because consumers are rethinking when, how and why they drink. - See the full report here.

Between the lines: - The report frames GLP-1s as a behavior story, not just a pharmaceutical story. - That matters because consumer shifts can outlast prescriptions and spread to non-users in the same household. - For brands, the bigger risk may be misreading the size of the audience and the speed of the change.

What's next: - Ideally says companies that understand how appetite is changing will be better positioned to adjust products, packaging and messaging. - The report suggests more pressure on snack and beverage makers as household habits continue to evolve. - Brands are likely to focus more on occasion-based demand, not just category substitution.

The bottom line: - Ideally’s message is simple: GLP-1s are changing consumer behavior far beyond prescription data, and brands that ignore that footprint may be underestimating the market by a wide margin.